{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:52Z","timestamp":1794048832125,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Provincial Medical Science and Technology Research Project","award":["SBGJ202303042"],"award-info":[{"award-number":["SBGJ202303042"]}]},{"name":"Henan Provincial Key Research Projects of Higher Education Institutions","award":["24A320005"],"award-info":[{"award-number":["24A320005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03695-w","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:51:08Z","timestamp":1747720268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of initial empirical antibiotic regimens in severe community-acquired pneumonia: a network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"Suppl 2","key":"3695_CR1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America\/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27\u201372.","journal-title":"Clin Infect Dis"},{"key":"3695_CR2","doi-asserted-by":"crossref","unstructured":"Cilloniz C, Ferrer M, Liapikou A et al. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. Eur Respir J. 2018;51(3).","DOI":"10.1183\/13993003.02215-2017"},{"issue":"1","key":"3695_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13054-016-1414-2","volume":"20","author":"J Phua","year":"2016","unstructured":"Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely management measures in the first 24 hours. Crit Care. 2016;20(1):237.","journal-title":"Crit Care"},{"issue":"6","key":"3695_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/imj.15171","volume":"52","author":"D Tsai","year":"2022","unstructured":"Tsai D, Chiong F, Secombe P, et al. Epidemiology and microbiology of severe community-acquired pneumonia in central Australia: a retrospective study. Intern Med J. 2022;52(6):1048\u201356.","journal-title":"Intern Med J"},{"key":"3695_CR5","doi-asserted-by":"crossref","unstructured":"Wang S, Tang J, Tan Y et al. Prevalence of atypical pathogens in patients with severe pneumonia: a systematic review and meta-analysis. BMJ Open. 2023;13(4).","DOI":"10.1136\/bmjopen-2022-066721"},{"issue":"7","key":"3695_CR6","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"3695_CR7","doi-asserted-by":"crossref","unstructured":"Martin-Loeches I, Torres A, Nagavci B et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023;61(4).","DOI":"10.1183\/13993003.00735-2022"},{"issue":"1","key":"3695_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.chest.2023.08.008","volume":"165","author":"AD Bai","year":"2024","unstructured":"Bai AD, Srivastava S, Wong BKC, et al. Comparative effectiveness of first-line and alternative antibiotic regimens in hospitalized patients with nonsevere community-acquired pneumonia: a multicenter retrospective cohort study. Chest. 2024;165(1):68\u201378.","journal-title":"Chest"},{"issue":"12","key":"3695_CR9","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1093\/jac\/dkad301","volume":"78","author":"A Greco Kinney","year":"2023","unstructured":"Greco Kinney A, Kovacic Scherrer N, Sarkar S, et al. \u03b2-Lactams plus Doxycycline versus Azithromycin for treatment of severe community-acquired pneumonia in critically ill patients. J Antimicrob Chemother. 2023;78(12):2816\u201323.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3695_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3346\/jkms.2017.32.1.77","volume":"32","author":"JH Lee","year":"2017","unstructured":"Lee JH, Kim HJ, Kim YH. Is \u03b2-Lactam plus macrolide more effective than \u03b2-Lactam plus fluoroquinolone among patients with severe community-acquired pneumonia? A systemic review and meta-analysis. J Korean Med Sci. 2017;32(1):77\u201384.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"3695_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/cid\/ciab863","volume":"75","author":"M Uddin","year":"2022","unstructured":"Uddin M, Mohammed T, Metersky M, et al. Effectiveness of beta-lactam plus doxycycline for patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2022;75(1):118\u201324.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3695_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"3695_CR13","unstructured":"Wells GA, Shea B, O\u2019Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"3695_CR14","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.","DOI":"10.1136\/bmj.l4898"},{"issue":"4","key":"3695_CR15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/1536867X1501500403","volume":"15","author":"IR White","year":"2015","unstructured":"White IR. Network meta-analysis. Stata J. 2015;15(4):951\u201385.","journal-title":"Stata J"},{"issue":"2","key":"3695_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"3695_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, Jackson D, Barrett J, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi\u2010arm studies. Res Synthesis Methods. 2012;3(2):98\u2013110.","journal-title":"Res Synthesis Methods"},{"key":"3695_CR18","doi-asserted-by":"crossref","unstructured":"Shim S, Yoon B-H, Shin I-S et al. Network meta-analysis: application and practice using stata. Epidemiol Health. 2017;39.","DOI":"10.4178\/epih.e2017047"},{"issue":"3","key":"3695_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol. 2012;41(3):818\u201327.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"3695_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s00134-002-1325-3","volume":"28","author":"J Rello","year":"2002","unstructured":"Rello J, Catal\u00e1n M, D\u00edaz E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med. 2002;28(8):1030\u20135.","journal-title":"Intensive Care Med"},{"issue":"1","key":"3695_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1378\/chest.128.1.172","volume":"128","author":"O Leroy","year":"2005","unstructured":"Leroy O, Saux P, B\u00e9dos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest. 2005;128(1):172\u201383.","journal-title":"Chest"},{"issue":"Suppl 3","key":"3695_CR22","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1086\/591404","volume":"47","author":"DW Bratzler","year":"2008","unstructured":"Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the national pneumonia project. Clin Infect Dis. 2008;47(Suppl 3):S193\u2013201.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3695_CR23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","volume":"36","author":"I Martin-Loeches","year":"2010","unstructured":"Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36(4):612\u201320.","journal-title":"Intensive Care Med"},{"issue":"8","key":"3695_CR24","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1097\/CCM.0b013e31825151a8","volume":"40","author":"BZ Wilson","year":"2012","unstructured":"Wilson BZ, Anzueto A, Restrepo MI, et al. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med. 2012;40(8):2310\u20134.","journal-title":"Crit Care Med"},{"issue":"6","key":"3695_CR25","doi-asserted-by":"publisher","first-page":"R265","DOI":"10.1186\/cc13095","volume":"17","author":"C Adrie","year":"2013","unstructured":"Adrie C, Schwebel C, Garrouste-Orgeas M, et al. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit Care. 2013;17(6):R265.","journal-title":"Crit Care"},{"issue":"5","key":"3695_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/aas.12081","volume":"57","author":"J Karhu","year":"2013","unstructured":"Karhu J, Ala-Kokko TI, Ohtonen P, et al. Severe community-acquired pneumonia treated with \u03b2-lactam-respiratory quinolone vs. \u03b2-lactam-macrolide combination. Acta Anaesthesiol Scand. 2013;57(5):587\u201393.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"3695_CR27","doi-asserted-by":"publisher","first-page":"e0178022","DOI":"10.1371\/journal.pone.0178022","volume":"12","author":"A Ceccato","year":"2017","unstructured":"Ceccato A, Cilloniz C, Ranzani OT, et al. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: a post-hoc exploratory analysis of a randomized controlled trial. PLoS ONE. 2017;12(6):e0178022.","journal-title":"PLoS ONE"},{"issue":"1","key":"3695_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12871-017-0376-5","volume":"17","author":"T Rahmel","year":"2017","unstructured":"Rahmel T, Asmussen S, Karlik J, et al. Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS. BMC Anesthesiol. 2017;17(1):78.","journal-title":"BMC Anesthesiol"},{"issue":"1","key":"3695_CR29","doi-asserted-by":"publisher","first-page":"18406","DOI":"10.1038\/s41598-019-54922-4","volume":"9","author":"A Ito","year":"2019","unstructured":"Ito A, Ishida T, Tachibana H, et al. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis. Sci Rep. 2019;9(1):18406.","journal-title":"Sci Rep"},{"issue":"12","key":"3695_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jiac.2019.05.027","volume":"25","author":"J Suzuki","year":"2019","unstructured":"Suzuki J, Sasabuchi Y, Hatakeyama S, et al. Azithromycin plus \u03b2-lactam versus levofloxacin plus \u03b2-lactam for severe community-acquired pneumonia: a retrospective nationwide database analysis. J Infect Chemother. 2019;25(12):1012\u20138.","journal-title":"J Infect Chemother"},{"issue":"1","key":"3695_CR31","doi-asserted-by":"publisher","first-page":"105836","DOI":"10.1016\/j.ijantimicag.2019.10.017","volume":"55","author":"E Kyriazopoulou","year":"2020","unstructured":"Kyriazopoulou E, Sinapidis D, Halvatzis S, et al. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: a matched comparator study. Int J Antimicrob Agents. 2020;55(1):105836.","journal-title":"Int J Antimicrob Agents"},{"key":"3695_CR32","doi-asserted-by":"crossref","unstructured":"Oh S, Jang W, Kim B. Is the fluoroquinolone combination necessary for empirical antibiotic regimen in severe community-acquired pneumonia? Postgrad Med. 2024.","DOI":"10.1080\/00325481.2024.2347830"},{"issue":"1","key":"3695_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13054-015-1051-1","volume":"19","author":"S Gattarello","year":"2015","unstructured":"Gattarello S, Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit Care. 2015;19(1):335.","journal-title":"Crit Care"},{"key":"3695_CR34","doi-asserted-by":"crossref","unstructured":"Raeven VM, Spoorenberg SMC, Boersma WG et al. Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohorts. BMC Infect Dis. 2016;16(1).","DOI":"10.1186\/s12879-016-1641-9"},{"key":"3695_CR35","doi-asserted-by":"crossref","unstructured":"Eljaaly K, Alshehri S, Aljabri A et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1).","DOI":"10.1186\/s12879-017-2495-5"},{"key":"3695_CR36","doi-asserted-by":"crossref","unstructured":"Eljaaly K, Aljabri A, Rabaan AA et al. Efficacy of empiric antibiotic coverage in community-acquired pneumonia associated with each atypical bacteria: a meta-analysis. J Clin Med. 2021;10(19).","DOI":"10.3390\/jcm10194321"},{"issue":"4","key":"3695_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1124\/pharmrev.121.000300","volume":"73","author":"JA Kricker","year":"2021","unstructured":"Kricker JA, Page CP, Gardarsson FR, et al. Nonantimicrobial actions of macrolides: overview and perspectives for future development. Pharmacol Rev. 2021;73(4):233\u201362.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3695_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2213-2600(23)00412-5","volume":"12","author":"EJ Giamarellos-Bourboulis","year":"2024","unstructured":"Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12(4):294\u2013304.","journal-title":"Lancet Respir Med"},{"issue":"21","key":"3695_CR39","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"PF Dequin","year":"2023","unstructured":"Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931\u201341.","journal-title":"N Engl J Med"},{"key":"3695_CR40","doi-asserted-by":"publisher","first-page":"1181633","DOI":"10.3389\/fcimb.2023.1181633","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Liu L, Zhang H, et al. Severe problem of macrolides resistance to common pathogens in China. Front Cell Infect Microbiol. 2023;13:1181633.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"3695_CR41","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/jac\/dkac170","volume":"77","author":"G Wang","year":"2022","unstructured":"Wang G, Wu P, Tang R, et al. Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77(9):2353\u201363.","journal-title":"J Antimicrob Chemother"},{"key":"3695_CR42","doi-asserted-by":"crossref","unstructured":"Babonji AS, Alshehri SJ, Alturaiki AM. Clinical effectiveness and outcomes of azithromycin versus doxycycline containing regimen in inpatients with community acquired pneumonia: a retrospective cohort study. J Clin Pharm Ther. 2023;2023.","DOI":"10.1155\/2023\/8861376"},{"issue":"1","key":"3695_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s40001-022-00912-8","volume":"27","author":"RK Aldhahri","year":"2022","unstructured":"Aldhahri RK, Gabb SG, Shoaib OA, et al. Doxycycline vs. macrolides in combination with a \u03b2-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients. Eur J Med Res. 2022;27(1):279.","journal-title":"Eur J Med Res"},{"issue":"3","key":"3695_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/1574891X13666181024154526","volume":"13","author":"M Izadi","year":"2018","unstructured":"Izadi M, Dadsetan B, Najafi Z, et al. Levofloxacin versus ceftriaxone and azithromycin combination in the treatment of community acquired pneumonia in hospitalized patients. Recent Pat Antiinfect Drug Discov. 2018;13(3):228\u201339.","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"5","key":"3695_CR45","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1378\/chest.119.5.1420","volume":"119","author":"PM Houck","year":"2001","unstructured":"Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 Western States: 1993, 1995, and 1997. Chest. 2001;119(5):1420\u20136.","journal-title":"Chest"},{"issue":"6","key":"3695_CR46","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/archinte.162.6.682","volume":"162","author":"DS Battleman","year":"2002","unstructured":"Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162(6):682\u20138.","journal-title":"Arch Intern Med"},{"issue":"15","key":"3695_CR47","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1001\/archinte.161.15.1837","volume":"161","author":"GW Waterer","year":"2001","unstructured":"Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161(15):1837\u201342.","journal-title":"Arch Intern Med"},{"issue":"5","key":"3695_CR48","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1183\/09031936.06.00126004","volume":"27","author":"J Aspa","year":"2006","unstructured":"Aspa J, Rajas O, de Castro FR, et al. Impact of initial antibiotic choice on mortality from Pneumococcal pneumonia. Eur Respir J. 2006;27(5):1010\u20139.","journal-title":"Eur Respir J"},{"issue":"1","key":"3695_CR49","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/cc3934","volume":"10","author":"EM Mortensen","year":"2005","unstructured":"Mortensen EM, Restrepo MI, Anzueto A, et al. The impact of empiric antimicrobial therapy with a \u03b2-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care. 2005;10(1):R8.","journal-title":"Crit Care"},{"issue":"Supplement1","key":"3695_CR50","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1093\/jac\/dky530","volume":"74","author":"AA Bhalodi","year":"2019","unstructured":"Bhalodi AA, van Engelen TSR, Virk HS, et al. Impact of antimicrobial therapy on the gut microbiome. J Antimicrob Chemother. 2019;74(Supplement1):i6\u201315.","journal-title":"J Antimicrob Chemother"},{"key":"3695_CR51","doi-asserted-by":"crossref","unstructured":"Zuttion MSSR, Parimon T, Bora SA et al. Antibiotic use during influenza infection augments lung eosinophils that impair immunity against secondary bacterial pneumonia. J Clin Investig. 2024;134(21).","DOI":"10.1172\/JCI180986"},{"key":"3695_CR52","unstructured":"McCurdy S, Nenninger A, Sheets A et al. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the Delafloxacin phase 3 CABP trial. (1878\u20133511 (Electronic))."},{"key":"3695_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2021.01.032","volume":"104","author":"A Torres","year":"2021","unstructured":"Torres A, Garrity-Ryan L, Kirsch C, et al. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. Int J Infect Dis. 2021;104:501\u20139.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"3695_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10096-005-1295-9","volume":"24","author":"E Garc\u00eda V\u00e1zquez","year":"2005","unstructured":"Garc\u00eda V\u00e1zquez E, Mensa J, Mart\u00ednez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis. 2005;24(3):190\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03695-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:22:39Z","timestamp":1747722159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3695"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03695-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6121400\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis; ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not include the participant\u2019s identification image or other personal or clinical details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"246"}}